Biomea Fusion to Present at Oppenheimer’s 32nd Annual Virtual Healthcare Conference

Rhea-AI Summary

Biomea Fusion, a clinical-stage biopharmaceutical company, announced its participation in the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 16, 2022. CEO Thomas Butler will engage in a fireside chat at 7:00 AM Pacific Time. The company focuses on developing novel irreversible covalent small molecules aimed at treating genetically defined cancers and metabolic diseases. They utilize their proprietary FUSION™ System to advance therapeutic agents targeting key oncogenic drivers.

Investors can access the audio webcast on the company's website in the Investor Relations section.

REDWOOD CITY, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible covalent small molecules to treat and improve the lives of patients with genetically defined cancers and metabolic diseases, today announced that it is scheduled to participate in a fireside chat at the Oppenheimer 32^nd Annual Virtual Healthcare Conference on Wednesday, March 16, 2022 at 7:00am Pacific Time. Thomas Butler, Biomea’s CEO and Chairman of the Board, will participate in the fireside chat.

An audio webcast for this conference will be available on the Company’s website at www.biomeafusion.com in the Investor Relations section.

About Biomea Fusion

Biomea Fusion is a biopharmaceutical company focused on the discovery and development of irreversible small molecules to treat patients with genetically defined cancers and metabolic diseases. An irreversible small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional reversible drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response. The company is utilizing its proprietary FUSION™ System to advance a pipeline of irreversible-binding therapeutic agents against key oncogenic drivers of cancer and metabolic diseases. Biomea Fusion’s goal is to utilize its capabilities and platform to become a leader in developing irreversible small molecules in order to maximize the clinical benefit when treating various cancers and metabolic diseases.

Contact:

Van Sandwick
Director, Investor Relations & Corporate Development
vsandwick@biomeafusion.com
(650) 460-7759

FAQ

What is Biomea Fusion's participation in the Oppenheimer 32nd Annual Virtual Healthcare Conference?

Biomea Fusion will participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference on March 16, 2022, with CEO Thomas Butler in a fireside chat at 7:00 AM Pacific Time.

What is the focus of Biomea Fusion in the biopharmaceutical industry?

Biomea Fusion focuses on discovering and developing irreversible small molecules for treating genetically defined cancers and metabolic diseases.

How can investors access the audio webcast for the conference?

Investors can access the audio webcast of the conference on Biomea Fusion's website in the Investor Relations section.

What is the advantage of using irreversible small molecules according to Biomea Fusion?

Irreversible small molecules form permanent bonds to target proteins, offering advantages like greater selectivity, lower drug exposure, and more durable responses compared to conventional drugs.

What is the purpose of Biomea Fusion's FUSION™ System?

The FUSION™ System is used by Biomea Fusion to advance a pipeline of irreversible-binding therapeutic agents targeting key drivers of cancer and metabolic diseases.